| ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. | ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation.
Esposito D, Pant I, Shen Y, Qiao RF, Yang X, Bai Y, Jin J, Poulikakos PI, Aaronson SA., Free PMC Article | 02/26/2022 |
| Whole genome sequencing reveals a frameshift mutation and a large deletion in YY1AP1 in a girl with a panvascular artery disease. | Whole genome sequencing reveals a frameshift mutation and a large deletion in YY1AP1 in a girl with a panvascular artery disease.
Raggio V, Dell'Oca N, Simoes C, Tapié A, Medici C, Costa G, Rodriguez S, Greif G, Garrone E, Rovella ML, Gonzalez V, Halty M, González G, Shin JY, Shin SY, Kim C, Seo JS, Graña M, Naya H, Spangenberg L., Free PMC Article | 02/5/2022 |
| KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP. | KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y, Yang R, Ding J, Zhu F, Zhu C, Xu Q, Cai J. | 01/8/2022 |
| CUL4A promotes proliferation and inhibits apoptosis of colon cancer cells via regulating Hippo pathway. | CUL4A promotes proliferation and inhibits apoptosis of colon cancer cells via regulating Hippo pathway.
Yi LJ, Yi LJ, Ding N, Ren J. | 06/26/2021 |
| Prostaglandin E2 and its receptor EP2 trigger signaling that contributes to YAP-mediated cell competition. | Prostaglandin E(2) and its receptor EP2 trigger signaling that contributes to YAP-mediated cell competition.
Ishihara E, Nagaoka Y, Okuno T, Kofuji S, Ishigami-Yuasa M, Kagechika H, Kamimura K, Terai S, Yokomizo T, Sugimoto Y, Fujita Y, Suzuki A, Nishina H., Free PMC Article | 12/12/2020 |
| The results suggest that YAP/TAZ may be modulating cell volume in combination with cytoskeletal tension during cell cycle progression. | YAP and TAZ regulate cell volume.
Perez-Gonzalez NA, Rochman ND, Yao K, Tao J, Le MT, Flanary S, Sablich L, Toler B, Crentsil E, Takaesu F, Lambrus B, Huang J, Fu V, Chengappa P, Jones TM, Holland AJ, An S, Wirtz D, Petrie RJ, Guan KL, Sun SX., Free PMC Article | 05/16/2020 |
| This is the first report of biallelic YY1AP1 variants in noncoding regions and just the second family with multiple affected siblings. | Identification of pathogenic YY1AP1 splice variants in siblings with Grange syndrome by whole exome sequencing.
Rath M, Spiegler S, Strom TM, Trenkler J, Kroisel PM, Felbor U., Free PMC Article | 02/8/2020 |
| Hemorrhagic stroke and renovascular hypertension with Grange syndrome arising from a novel pathogenic variant in YY1AP1. | Hemorrhagic stroke and renovascular hypertension with Grange syndrome arising from a novel pathogenic variant in YY1AP1.
Saida K, Kim CA, Ceroni JRM, Bertola DR, Honjo RS, Mitsuhashi S, Takata A, Mizuguchi T, Miyatake S, Miyake N, Matsumoto N. | 12/28/2019 |
| Study proposed that the overexpression of YAP and TAZ around the human molluscum contagiosum (MC) virus infected skin lesions supports the hypothesis that the Hippo signaling pathway plays a key role in the development of MC. It is also conceivable that MCV contributes to the development of an infectious environment by increasing the expression of YAP/TAZ and subsequently inhibiting TBK1. | Expression of YAP and TAZ in molluscum contagiosum virus infected skin.
Seo HM, Moon GT, Song YM, Gee HY, Park YM, Lee JY, Lee JH. | 11/2/2019 |
| Data indicate WW-binding protein 2 (WBP2) as an important co-factor of YY1 associated protein 1 (YAP) that enhances YAP/TEAD-mediated gene transcription. | A genome-wide screen identifies YAP/WBP2 interplay conferring growth advantage on human epidermal stem cells.
Walko G, Woodhouse S, Pisco AO, Rognoni E, Liakath-Ali K, Lichtenberger BM, Mishra A, Telerman SB, Viswanathan P, Logtenberg M, Renz LM, Donati G, Quist SR, Watt FM., Free PMC Article | 12/22/2018 |
| Loss-of-Function Mutations in YY1AP1 Lead to Grange Syndrome and a Fibromuscular Dysplasia-Like Vascular Disease. | Loss-of-Function Mutations in YY1AP1 Lead to Grange Syndrome and a Fibromuscular Dysplasia-Like Vascular Disease.
Guo DC, Duan XY, Regalado ES, Mellor-Crummey L, Kwartler CS, Kim D, Lieberman K, de Vries BBA, Pfundt R, Schinzel A, Kotzot D, Shen X, Yang ML, University of Washington Center for Mendelian Genomics, Bamshad MJ, Nickerson DA, Gornik HL, Ganesh SK, Braverman AC, Grange DK, Milewicz DM., Free PMC Article | 05/27/2017 |
| YY1AP1 may serve as a key molecular target for EpCAM(+) AFP(+) HCC subtype | Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma.
Zhao X, Parpart S, Takai A, Roessler S, Budhu A, Yu Z, Blank M, Zhang YE, Jia HL, Ye QH, Qin LX, Tang ZY, Thorgeirsson SS, Wang XW., Free PMC Article | 12/19/2015 |
| HCCA2 may play a novel role in cell cycle regulation. | Hepatocellular carcinoma-associated gene 2 interacts with MAD2L2.
Li L, Shi Y, Wu H, Wan B, Li P, Zhou L, Shi H, Huo K. | 01/21/2010 |
| YY1AP is a novel co-activator of YY1 | YY1AP, a novel co-activator of YY1.
Wang CY, Liang YJ, Lin YS, Shih HM, Jou YS, Yu WC. | 01/21/2010 |
| human liver cancer associated gene | [Clone of a novel liver cancer associated gene and analysis of the secondary structures of the predicted protein].
Wang Z, Hu G, Wang H, Wu M. | 01/21/2010 |